We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.
- Authors
Opar, Alisa
- Abstract
The article reports on the entering of AstraZeneca Pharmaceuticals LP into a world licensing agreement for Rigel Pharmaceuticals' Inc. drug fostamatinib disodium (R-788), an oral spleen tyrosine kinase (SYK) that is used in treating rheumatoid arthritis (RA). It states that the protein kinase inhibitors could be effective in reducing the inflammatory pathways that are activated in RA. It mentions that pharmaceutical companies are developing small molecules which targets the janus kinase (JAK).
- Subjects
ASTRAZENECA Pharmaceuticals LP; RIGEL Pharmaceuticals Inc.; PROTEIN-tyrosine kinases; ORAL medicine; ALTERNATIVE treatment for rheumatoid arthritis; INFLAMMATION; PHARMACEUTICAL industry
- Publication
Nature Reviews Drug Discovery, 2010, Vol 9, Issue 4, p257
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd3155